There are few reports describing the association between antiphospholipid antibodies, including the lupus anticoagulant, and bone marrow or peripheral stem cell transplantation. Autoimmune syndromes and autoantibodies such as lupus anticoagulant and anticardiolipin antibodies have been described following allogeneic bone marrow or peripheral blood stem cell transplantation, particularly in patients who develop chronic graft-versushost disease (GVHD). The association between Lupus anticoagulant and acute GVHD has not been previously described. We report a patient who developed a de novo lupus anticoagulant on day +34 after a matched-related allogeneic peripheral stem cell transplant. No clinical evidence of systemic thrombosis was observed and the lupus anticoagulant disappeared following immunosuppressive therapy with a combination of steroids and infliximab. Bone Marrow Transplantation (2003) 31, 129-131. doi:10.1038/sj.bmt.1703794 Keywords: lupus anticoagulant; acute GVHD; bone marrow transplantation; peripheral stem cell transplantation When allogeneic bone marrow or peripheral stem cells are the source of stem cells, donor-derived T cells recognize and react to histoincompatible recipient antigens and cells, a phenomenon that forms the basis for the development of graft-versus-host disease (GVHD).
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1 GVHD remains a major complication of allogeneic bone marrow and peripheral stem cell transplantation (BM/PSCT). Autoimmune syndromes and autoantibodies including lupus anticoagulant and anticardiolipin antibodies have been described following allogeneic BM/PSCT, particularly in patients who develop chronic GVHD. 2, 3 The lupus anticoagulant is an antibody that binds to a complex of anionic phospholipid-bound prothrombin, resulting in prolongation of phospholipid-dependent clotting times. 4 Newly acquired lupus anticoagulant has been reported in association with chronic GVHD, 5 but not with acute GVHD (aGVHD). We report a case of an acquired lupus anticoagulant that developed on day +34 after a matchedrelated allogeneic peripheral stem cell transplant.
Case report
A 28-year-old man diagnosed with aplastic anemia received a matched-related allogeneic PSCT. The conditioning regimen included cyclophosphamide at a daily dose of 50 mg/ kg on days À5 to À2 and antithymocyte globulin (ATG) at a dose of 30 mg/kg administered on days À4 to À2, given 12 h after cyclophosphamide. Immunosuppression consisted of tacrolimus at a dose of 0.03 mg/kg daily and methotrexate at a dose of 10 mg/m 2 on day +1 and 5 mg/m 2 on days +3, +6 and +11. The patient's immediate post-transplant course was uneventful with engraftment on day +16 and discharge from the unit on day +24. The patient presented to the bone marrow transplant unit on day +34 with symptoms suggestive of gastrointestinal aGVHD including abdominal pain and bloody diarrhea. 
Discussion
There are few reports describing the association between antiphospholipid antibodies, including the lupus anticoagulant, and BM or PSCT. Lupus anticoagulant is the main antibody comprising in the group of antiphospholipid antibodies. The criteria used to demonstrate a lupus anticoagulant include: an increased clotting time in a phospholipid-dependent coagulation test, evidence of an inhibitor demonstrated by an incomplete correction of the clotting time on mixing with normal plasma, and confirmation of phospholipid dependence of the antibody. 4, 6 Autoimmune syndromes and autoantibodies have been suggested to develop following allogeneic and autologous BM/PSCT. Greeno et al, 7 in a retrospective analysis of 1292 patients post-transplantation (465 autologous and 827 allogeneic), reported that 3% of the patients developed a de novo lupus inhibitor. The development of inhibitors in that analysis was associated with several factors including use of cyclosporine A or T-cell depletion for GVHD prophylaxis, use of busulfan/cyclophosphamide (BUCY) combination as the preparative regimen and the occurrence of viral infections primarily cytomegalovirus (CMV), herpes simplex virus (HSV) and varicella zoster virus (VZV). 7 Lupus inhibitors were not associated with the development of aGVHD, or with any pretransplant clinical diagnosis other than Hurler's syndrome. Similarly, Sanmarco et al 2 described that several factors other than allogeneic reaction particularly viral infections with CMV, herpes virus and hepatitis could have been responsible for autoantibody formation after autologous or allogeneic BM/PSCT. The development of autoantibodies did not appear to be associated with GVHD, but it was noted that most of the patients received cyclophosphamide as part of the conditioning regimen. 2 On the other hand, various authors have suggested that both allogeneic and autologous BM/PSCT play a crucial role in the treatment of different autoimmune entities such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and a wide variety of different diseases where autoimmunity is an important component of the clinical picture. 8 Significant clinical remissions after autologous and allogeneic transplantation have been reported in patients with SLE or RA, refractory to standard therapy otherwise. Also, disappearance of a lupus anticoagulant following allogeneic BMT in a patient with no clinical evidence of SLE has been described in the medical literature. 9 Rauch et al, 10 described that immunization of mice with phosphatidylethanolamine (PE) in the hexagonal II phase, but not the bilayer phase, resulted in the induction of anti-phospholipid antibodies. 10 Similarly, hexagonal (II) PE is specifically recognized by lupus anticoagulant antibodies in SLE patients and may play a role in the etiology of the disease. We speculate that cell membrane injury as a result of allogeneic BM/PSCT (probably by direct allograft effect or cytotoxic effect of chemotherapy) or autologous BM/PSCT (by cytotoxic effect of chemotherapy) might expose antigens such as hexagonal phase lipids, not otherwise present in the normal bilayer of the intact cell membrane. These hexagonal phase lipids could serve as an epitope for the development of antiphospholipid antibodies such as the lupus inhibitors. 10 Our case is the first to demonstrate that a lupus anticoagulant can develop during the acute phase of GVHD. The absence of a lupus anticoagulant in the donor argues against allograft transmission of the autoantibodies into the recipient. Additionally, our patient did not have clinical or serologic evidence of a viral infection like CMV, HSV or VZV, which have been described to be responsible for autoantibody formation after autologous or allogeneic BM/PSCT in several series. 2, 7 Factor VIII levels were not measured as failure to correct the prolonged aPTT with mixing studies makes the possibility of a deficiency unlikely. Anticoagulation therapy was not initiated in our patient as he did not develop evidence of thrombosis and the prolonged aPTT was an incidental finding. However, the authors believe that anticoagulation therapy needs to be considered in post-BM/PSCT (allogeneic or autologous) patients, who present with thrombosis in association with a de novo lupus anticoagulant or other antiphospholipid antibodies. Choice and duration of anticoagulation therapy have to be decided on a case-by-case basis.
In conclusion, we believe there are three possible mechanisms that could explain the de novo development of the lupus anticoagulant in this patient. First, cell membrane damage by direct allograft effect (GI-aGVHD in our patient). Second, damage of the cell membrane secondary to the cytotoxic effect of chemotherapy namely cyclophosphamide. Third, a combined effect of both direct allograft and cyclophosphamide. Our case is unique as it demonstrates that a lupus anticoagulant can develop in association with aGVHD and its true incidence is probably underestimated. The disappearance of the lupus anticoagulant following immunosuppressive therapy with steroids and later infliximab is equally important and has never been described before. Autoimmunity in acute and chronic GVHD might represent a continuum rather than distinct separate entities.
